A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans

Journal of Lipid Research

Volumn 53, Issue 12, 2012, Pages 2734-2746

  Van De Pas, Niek C A ^a,b   Woutersen, Ruud A ^a,b   Van Ommen, Ben ^a   Rietjens, Ivonne M C M ^a,b   De Graaf, Albert A ^a  

^a TNO   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

HDL cholesterol; LDL cholesterol; Mutations; PBK modeling; Plasma cholesterol

Indexed keywords

CARRIER PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CALIBRATION; CATALYSIS; CHEMICAL REACTION; CHOLESTEROL BLOOD LEVEL; COMPUTER MODEL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HUMAN; KINETICS; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMITH LEMLI OPITZ SYNDROME; VALIDATION PROCESS;

ANIMALS; CHOLESTEROL; HUMANS; KINETICS; MICE; MODELS, BIOLOGICAL;

EID: 84869021740     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M031930     Document Type: Article

References (70)

1. Fell, D. 1997 . Understanding the control of metabolism. Portland Press, London, UK.
2. Rietjens, I. M., M. G. Boersma, M. Zaleska, and A. Punt. 2008. Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicol. In Vitro . 22: 1890 - 1901.
3. Reddy, M. B., R. S. H. Yang, H. J. Clewell, and M. E. Andersen. 2005. Physiologically based pharmacokinetic modeling. John Wiley & Sons, Inc., Hoboken, NJ.
4. van Schalkwijk, D. B., A. A. de Graaf, B. van Ommen, K. van Bochove, P. C. Rensen, L. M. Havekes, N. C. van de Pas, H. C. Hoefsloot, J. van der Greef, and A. P. Freidig. 2009. Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J. Lipid Res. 50: 2398 - 2411.
5. Adiels, M., C. Packard, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S. O. Olofsson, M. R. Taskinen, and J. Boren. 2005. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J. Lipid Res. 46: 58 - 67.
6. Packard, C. J., and J. Shepherd. 1997. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17: 3542 - 3556.
7. Ratushnyi, A. V., V. A. Likhoshvai, E. V. Ignat'eva, Y. G. Matushkin, I. I. Goryanin, and N. A. Kolchanov. 2003. A computer model of the gene network of the cholesterol biosynthesis regulation in the cell: analysis of the effect of mutations. Dokl. Biochem. Biophys. 389: 90 - 93.
8. Rosamond, W., K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, S. M. Hailpern, M. Ho, V. Howard, B. Kissela, et al. 2008. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 117: e25 - e146.
9. Glassberg, H., and D. J. Rader. 2008. Management of lipids in the prevention of cardiovascular events. Annu. Rev. Med. 59: 79 - 94.
10. Lusis, A. J. 2000. Atherosclerosis. Nature. 407: 233 - 241.
11. van de Pas, N. C., A. E. Soffers, A. P. Freidig, B. van Ommen, R. A. Woutersen, I. M. Rietjens, and A. A. de Graaf. 2010. Systematic construction of a conceptual minimal model of plasma cholesterol levels based on knockout mouse phenotypes. Biochim. Biophys. Acta. 1801: 646 - 654.
12. van de Pas, N. C., R. A. Woutersen, B. van Ommen, I. M. Rietjens, and A. A. de Graaf. 2011. A physiologically-based kinetic model for the prediction of plasma cholesterol concentrations in the mouse. Biochim. Biophys. Acta . 1811: 333 - 342.
13. Dietschy, J. M., and S. D. Turley. 2002. Control of cholesterol turnover in the mouse. J. Biol. Chem. 277: 3801 - 3804.
14. Agellon, L. B., A. Walsh, T. Hayek, P. Moulin, X. C. Jiang, S. A. Shelanski, J. L. Breslow, and A. R. Tall. 1991. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266: 10796 - 10801.
15. Zhong, S., D. S. Sharp, J. S. Grove, C. Bruce, K. Yano, J. D. Curb, and A. R. Tall. 1996. Increased coronary heart disease in Japanese- American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97: 2917 - 2923.
16. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109 - 2122.
17. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490 - 497.
18. Davidson, M. H., J. M. McKenney, C. L. Shear, and J. H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48: 1774 - 1781.
19. Brown, R. P., M. D. Delp, S. L. Lindstedt, L. R. Rhomberg, and R. P. Beliles. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 13: 407 - 484.
20. Potter, L. K., D. L. Sprecher, M. C. Walker, and F. L. Tobin. 2009. Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro. J. Lipid Res. 50: 2222 - 2234.
21. Morton, R. E., and D. J. Greene. 2003. The surface cholesteryl ester content of donor and acceptor particles regulates CETP: a liposome-based approach to assess the substrate properties of lipoproteins. J. Lipid Res. 44: 1364 - 1372.
22. Carroll, M. D., D. A. Lacher, P. D. Sorlie, J. I. Cleeman, D. J. Gordon, M. Wolz, S. M. Grundy, and C. L. Johnson. 2005. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 294: 1773 - 1781.
23. Groener, J. E., L. M. Scheek, E. van Ramshorst, X. H. Krauss, and A. van Tol. 1998. Delayed increase in high density lipoprotein-phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. Atherosclerosis. 137: 311 - 319.
24. Pullinger, C. R., C. Eng, G. Salen, S. Shefer, A. K. Batta, S. K. Erickson, A. Verhagen, C. R. Rivera, S. J. Mulvihill, M. J. Malloy, et al. 2002. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110: 109 - 117.
25. Punt, A., A. Paini, M. G. Boersma, A. P. Freidig, T. Delatour, G. Scholz, B. Schilter, P. J. van Bladeren, and I. M. Rietjens. 2009. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol. Sci. 110: 255 - 269.
26. Lupfert, C., and A. Reichel. 2005. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem. Biodivers. 2: 1462 - 1486.
27. Hissink, A. M., B. van Ommen, J. Kruse, and P. J. van Bladeren. 1997. A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. Toxicol. Appl. Pharmacol. 145: 301 - 310.
28. Quick, D. J., and M. L. Shuler. 1999. Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol. Prog. 15: 540 - 555.
29. Tabas, I. 1997. Free cholesterol-induced cytotoxicity. Trends Cardiovasc. Med. 7: 256 - 263.
30. Davidson, M. H., and P. P. Toth. 2004. Comparative effects of lipid-lowering therapies. Prog. Cardiovasc. Dis. 47: 73 - 104.
31. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105: 2159 - 2165.
32. Katsnelson, A. 2010. Good news for 'good' cholesterol. Nature. 468: 354.
33. Schwartz, C. C., J. M. VandenBroek, and P. S. Cooper. 2004. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45: 1594 - 1607.
34. Kervizic, G., and L. Corcos. 2008. Dynamical modeling of the cholesterol regulatory pathway with Boolean networks. BMC Syst. Biol. 2: 99.
35. Knoblauch, H., H. Schuster, F. C. Luft, and J. Reich . 2000. A pathway model of lipid metabolism to predict the effect of genetic variability on lipid levels. J. Mol. Med. 78: 507 - 515.
36. Muzaffer Demirezen, E. 2009. A simulation model for blood cholesterol dynamics and related disorders. M.S. thesis. Graduate Program in Industrial Engineering, Bogazici University, Istanbul, Turkey.
37. Ostlund, R. E., Jr . 1993. A minimal model for human whole body cholesterol metabolism. Am. J. Physiol. 265: E513 - E520.
38. Hubner, K., T. Schwager, K. Winkler, J. G. Reich, and H. G. Holzhutter. 2008. Computational lipidology: predicting lipoprotein density profiles in human blood plasma. PLOS Comput. Biol. 4: e1000079.
39. Tiemann, C. A., J. Vanlier, P. A. J. Hilbers, and N. A. W. van Riel. 2011. Parameter adaptations during phenotype transitions in progressive diseases. BMC Syst. Biol. 5: 174 - 187.
40. Dietschy, J. M., and S. D. Turley. 2004. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45: 1375 - 1397.
41. Rinninger, F., S. Jaeckle, and R. C. Pittman. 1993. A pool of reversibly cell-associated cholesteryl esters involved in the selective uptake of cholesteryl esters from high-density lipoproteins by Hep G2 hepatoma cells. Biochim. Biophys. Acta. 1166: 275 - 283.
42. Tayfun Güldür, T., N. Bayraktar, Ö. Kaynar, G. Beker, M. Koçer, and H. Özcan. 2007. Excretion rate and composition of skin surface lipids on the foreheads of adult males with type IV hyperlipoproteinemia. J. Basic Clin. Physiol. Pharmacol. 18: 21-35.
43. Robosky, L. C., K. Wade, D. Woolson, J. D. Baker, M. L. Manning, D. A. Gage, and M. D. Reily. 2008. Quantitative evaluation of sebum lipid components with nuclear magnetic resonance. J. Lipid Res. 49: 686 - 692.
44. Waterham, H. R., F. A. Wijburg, R. C. Hennekam, P. Vreken, B. T. Poll-The, L. Dorland, M. Duran, P. E. Jira, J. A. Smeitink, R. A. Wevers, et al. 1998. Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am. J. Hum. Genet. 63: 329 - 338.
45. Punt, A., A. P. Freidig, T. Delatour, G. Scholz, M. G. Boersma, B. Schilter, P. J. van Bladeren, and I. M. Rietjens. 2008. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicol. Appl. Pharmacol. 231: 248 - 259.
46. Calabresi, L., L. Pisciotta, A. Costantin, I. Frigerio, I. Eberini, P. Alessandrini, M. Arca, G. B. Bon, G. Boscutti, G. Busnach, et al. 2005. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler. Thromb. Vasc. Biol. 25: 1972 - 1978.
47. Clarke, R., C. Frost, R. Collins, P. Appleby, and R. Peto. 1997. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ. 314: 112 - 117.
48. Nicholls, S. J., E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Y. Desai, S. L. Hazen, et al. 2007. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 297: 499 - 508.
49. Kastelein, J. J., S. I. van Leuven, L. Burgess, G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, et al. 2007. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356: 1620 - 1630.
50. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al.: 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466: 707 - 713.
51. Retzlaff, J. A., W. N. Tauxe, J. M. Kiely, and C. F. Stroebel. 1969. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 33: 649 - 661.
52. Honda, A., T. Yoshida, N. Tanaka, Y. Matsuzaki, B. He, J. Shoda, and T. Osuga. 1995. Accumulation of 7 alpha-hydroxycholesterol in liver tissue of patients with cholesterol gallstones. J. Gastroenterol. 30: 651 - 656.
53. Crouse, J. R., S. M. Grundy, and E. H. Ahrens, Jr. 1972. Cholesterol distribution in the bulk tissues of man: variation with age. J. Clin. Invest. 51: 1292 - 1296.
54. Chobanian, A. V., and W. Hollander. 1965. Tissue distribution of cholesterol and 24-dehydrocholesterol during chronic triparanol therapy. J. Lipid Res. 6: 37 - 42.
55. Ranheim, T., B. Halvorsen, A. C. Huggett, R. Blomhoff, and C. A. Drevon. 1995. Effect of a coffee lipid (cafestol) on regulation of lipid metabolism in CaCo-2 cells. J. Lipid Res. 36: 2079 - 2089.
56. McNamara, D. J., E. H. Ahrens, Jr ., P. Samuel, and J. R. Crouse. 1977. Measurement of daily cholesterol synthesis rates in man by assay of the fractional conversion of mevalonic acid to cholesterol. Proc. Natl. Acad. Sci. USA. 74: 3043 - 3046.
57. Dietschy, J. M., S. D. Turley, and D. K. Spady. 1993. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34: 1637 - 1659.
58. Dietschy, J. M., and W. G. Gamel. 1971. Cholesterol synthesis in the intestine of man: regional differences and control mechanisms. J. Clin. Invest. 50: 872 - 880.
59. Miettinen, T. A., and Y. A. Kesaniemi. 1989. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within- population variations of serum cholesterol levels. Am. J. Clin. Nutr. 49: 629 - 635.
60. Xie, C., S. D. Turley, and J. M. Dietschy. 2009. ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse. J. Lipid Res. 50: 1316 - 1329.
61. Gaffney, D., L. Forster, M. J. Caslake, D. Bedford, J. P. Stewart, G. Stewart, G. Wieringa, M. Dominiczak, J. P. Miller, and C. J. Packard. 2002. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis . 162: 33 - 43.
62. Gylling, H., and T. A. Miettinen . 1992 . Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes. J. Lipid Res. 33: 1361 - 1371.
63. Funke, H., A. von Eckardstein, P. H. Pritchard, J. J. Albers, J. J. Kastelein, C. Droste, and G. Assmann. 1991. A molecular defect causing fish eye disease: an amino acid exchange in lecithincholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc. Natl. Acad. Sci. USA. 88: 4855 - 4859.
64. Funke, H., A. von Eckardstein, P. H. Pritchard, M. Karas, J. J. Albers, and G. Assmann. 1991. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J. Clin. Invest. 87: 371 - 376.
65. Bennion, L. J., and S. M. Grundy. 1975. Effects of obesity and caloric intake on biliary lipid metabolism in man. J. Clin. Invest. 56: 996 - 1011.
66. Field, F. J., K. Watt, and S. N. Mathur. 2008. Origins of intestinal ABCA1-mediated HDL-cholesterol. J. Lipid Res. 49: 2605 - 2619.
67. Mott, S., L. Yu, M. Marcil, B. Boucher, C. Rondeau, and J. Genest, Jr. 2000. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis . 152: 457 - 468.
68. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr . 1981. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211: 584 - 586.
69. Jira, P. E., J. G. de Jong, F. S. Janssen-Zijlstra, U. Wendel, and R. A. Wevers. 1997. Pitfalls in measuring plasma cholesterol in the Smith-Lemli-Opitz syndrome. Clin. Chem. 43: 129 - 133.
70. Wanders, R. J., G. J. Romeijn, F. Wijburg, R. C. Hennekam, J. de Jong, R. A. Wevers, and G. Dacremont. 1997. Smith-Lemli-Opitz syndrome: deficient delta 7-reductase activity in cultured skin fibroblasts and chorionic villus fibroblasts and its application to pre- and postnatal detection. J. Inherit. Metab. Dis. 20: 432 - 436.